<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01960465</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-022-13S</org_study_id>
    <nct_id>NCT01960465</nct_id>
  </id_info>
  <brief_title>Race And CPAP Effectiveness</brief_title>
  <acronym>RACE</acronym>
  <official_title>Targeted Treatment of Obstructive Sleep Apnea to Reduce Cardiovascular Disparity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea (OSA) is a major public health problem in the U.S. and more than 35%&#xD;
      of Veterans are at high risk for OSA. OSA is associated with progression of hypertension, an&#xD;
      important health problem in Veterans. African Americans with OSA are at increased risk for&#xD;
      poorly controlled hypertension and its health consequences. Implementing a care plan to&#xD;
      increase the percentage of Veterans in whom blood pressure goals are achieved has been&#xD;
      prioritized by Veterans Administration hospitals. Recent studies show that hypertension&#xD;
      control can be improved with continuous positive airway pressure (CPAP) treatment of OSA. The&#xD;
      aim of this proposal is to examine and compare the effects of CPAP treatment on 24-hour&#xD;
      arterial blood pressure and central aortic blood pressure (measured non-invasively with a&#xD;
      cuff on the upper arm) in African American and other Veterans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obstructive Sleep Apnea (OSA) and hypertension are both common and severe problems in African&#xD;
      American individuals (as noted in the International Society on Hypertension in Blacks&#xD;
      consensus statement). CPAP treatment of OSA is effective in controlling hypertension in&#xD;
      patients with OSA, but has not been studied in African Americans, a high-risk population with&#xD;
      potentially large health gains. This is an area of significance because poorly controlled&#xD;
      hypertension leads to progression of cardiovascular disease (CVD) and morbidity in this&#xD;
      population. By identifying CPAP treatment-response and relevant moderators of this response&#xD;
      in African Americans with hypertension and OSA, targeted treatment of OSA can be implemented,&#xD;
      reducing the excess burden of CVD. The investigators will determine the relative magnitude of&#xD;
      hypertension response to CPAP treatment (ambulatory blood pressure and central aortic blood&#xD;
      pressure) in 220 African American and Veterans of other race(s) with hypertension and newly&#xD;
      diagnosed OSA (specific aim 1). The investigators will measure changes in pathogenic&#xD;
      biomarkers (urinary cumulative sympathetic nervous system activity and oxidative stress) that&#xD;
      are responsive to CPAP treatment in addition to hypertension assessments. Further, the&#xD;
      investigators will examine the role of excessive daytime sleepiness (EDS), a potentially&#xD;
      important moderator of treatment response, in these two patient populations (specific aim 2).&#xD;
      Finally, the investigators will adjust the outcomes assessment for the anticipated biological&#xD;
      heterogeneity among self-identified African Americans by measuring genetic ancestry&#xD;
      (exploratory aim). This award will provide the foundation for the goals of this research&#xD;
      program to reduce CVD disparity in diverse populations with targeted treatment of OSA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2015</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 Hour Ambulatory Blood Pressure</measure>
    <time_frame>3 months</time_frame>
    <description>Mean systolic and diastolic blood pressure measured over 24 hours with ambulatory monitor (Spacelabs).&#xD;
The change in blood pressure values were calculated as 3 months BP - baseline BP.&#xD;
The mean and standard deviation in the sample are noted below.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central Aortic Blood Pressure</measure>
    <time_frame>3 months</time_frame>
    <description>Central aortic blood pressure (CABP) measured noninvasively with a cuff (SphygmoCor XCEL).&#xD;
The change in CABP values were calculated as 3 months CABP - baseline CABP. The mean and standard deviation in the sample are noted below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Sympathetic Activity (Catecholamines) and Oxidative Stress (8-isoprostane)</measure>
    <time_frame>3 months</time_frame>
    <description>Urine samples from participants over 24 hours will be analyzed for catecholamines and overnight sample will be partitioned for measurement of oxidative stress.&#xD;
The change in urine catecholamine values were calculated as 3 months - baseline.&#xD;
The mean and standard deviation in the sample are noted below.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Sleep Apnea Syndromes</condition>
  <arm_group>
    <arm_group_label>African Americans</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>138 Self identified African American</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non African Americans</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>53 Caucasians and 29 Other race (non African-Americans) Veterans.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous positive airway pressure</intervention_name>
    <description>A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.</description>
    <arm_group_label>African Americans</arm_group_label>
    <arm_group_label>non African Americans</arm_group_label>
    <other_name>CPAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Self-identified African American and other Veterans (of self-identified race other&#xD;
             than African American)&#xD;
&#xD;
          -  Age: 30-70 years&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  Apnea hypopnea index (AHI) 15/hour on home sleep apnea test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past/current treatment of Obstructive Sleep Apnea or other primary sleep disorders&#xD;
&#xD;
          -  Active uncontrolled medical conditions&#xD;
&#xD;
          -  Shift work in past 6 months&#xD;
&#xD;
          -  Current drug use&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bharati Prasad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jesse Brown VA Medical Center, Chicago, IL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jesse Brown VA Medical Center, Chicago, IL</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 9, 2013</study_first_submitted>
  <study_first_submitted_qc>October 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <results_first_submitted>September 29, 2020</results_first_submitted>
  <results_first_submitted_qc>October 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2020</results_first_posted>
  <disposition_first_submitted>August 28, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>September 2, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 9, 2020</disposition_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CPAP treatment</keyword>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 8, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT01960465/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>January 2015 to August 2019, recruitment by chart review (results of home sleep apnea test) at Jesse Brown VA.&#xD;
Participants were contacted by phone, consented on screening/Visit 1.</recruitment_details>
      <pre_assignment_details>All participants had moderate to severe newly diagnosed/untreated OSA&gt; They were started on PAP therapy after visit 1.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>African Americans</title>
          <description>138 Self identified African American&#xD;
Continuous positive airway pressure: A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.</description>
        </group>
        <group group_id="P2">
          <title>Non African Americans</title>
          <description>53 Caucasians and 29 Other race (non African-Americans) Veterans.&#xD;
Continuous positive airway pressure: A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis population consisted of 191 participants, after accounting for drop-out and missing data for primary outcome of 24-hour BP.</population>
      <group_list>
        <group group_id="B1">
          <title>African Americans</title>
          <description>138 Self identified African American&#xD;
Continuous positive airway pressure: A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.</description>
        </group>
        <group group_id="B2">
          <title>Non African Americans</title>
          <description>53 Caucasians and 29 Other race (non African-Americans) Veterans.&#xD;
Continuous positive airway pressure: A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="138"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="220"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.74" spread="10.3"/>
                    <measurement group_id="B2" value="53.1" spread="10.4"/>
                    <measurement group_id="B3" value="53.5" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>24 hour blood pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130.55" spread="13.9"/>
                    <measurement group_id="B2" value="126.49" spread="13.6"/>
                    <measurement group_id="B3" value="129.02" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>24 Hour Ambulatory Blood Pressure</title>
        <description>Mean systolic and diastolic blood pressure measured over 24 hours with ambulatory monitor (Spacelabs).&#xD;
The change in blood pressure values were calculated as 3 months BP - baseline BP.&#xD;
The mean and standard deviation in the sample are noted below.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>African Americans</title>
            <description>138 Self identified African American&#xD;
Continuous positive airway pressure: A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.</description>
          </group>
          <group group_id="O2">
            <title>Non African Americans</title>
            <description>82 Other race (non African Americans) Veterans.&#xD;
Continuous positive airway pressure: A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.</description>
          </group>
        </group_list>
        <measure>
          <title>24 Hour Ambulatory Blood Pressure</title>
          <description>Mean systolic and diastolic blood pressure measured over 24 hours with ambulatory monitor (Spacelabs).&#xD;
The change in blood pressure values were calculated as 3 months BP - baseline BP.&#xD;
The mean and standard deviation in the sample are noted below.</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic BP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.93" spread="13"/>
                    <measurement group_id="O2" value="-0.64" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="9.3"/>
                    <measurement group_id="O2" value="-1.19" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Central Aortic Blood Pressure</title>
        <description>Central aortic blood pressure (CABP) measured noninvasively with a cuff (SphygmoCor XCEL).&#xD;
The change in CABP values were calculated as 3 months CABP - baseline CABP. The mean and standard deviation in the sample are noted below.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>African Americans</title>
            <description>138 Self identified African American&#xD;
Continuous positive airway pressure: A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.</description>
          </group>
          <group group_id="O2">
            <title>Non African Americans</title>
            <description>82 Other race (non African Americans) Veterans.&#xD;
Continuous positive airway pressure: A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.</description>
          </group>
        </group_list>
        <measure>
          <title>Central Aortic Blood Pressure</title>
          <description>Central aortic blood pressure (CABP) measured noninvasively with a cuff (SphygmoCor XCEL).&#xD;
The change in CABP values were calculated as 3 months CABP - baseline CABP. The mean and standard deviation in the sample are noted below.</description>
          <units>m/sec and percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulse Wave Velocity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="2.0"/>
                    <measurement group_id="O2" value="-0.23" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Augmentation Index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.20" spread="10.6"/>
                    <measurement group_id="O2" value="-0.68" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Sympathetic Activity (Catecholamines) and Oxidative Stress (8-isoprostane)</title>
        <description>Urine samples from participants over 24 hours will be analyzed for catecholamines and overnight sample will be partitioned for measurement of oxidative stress.&#xD;
The change in urine catecholamine values were calculated as 3 months - baseline.&#xD;
The mean and standard deviation in the sample are noted below.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>African Americans</title>
            <description>138 Self identified African American&#xD;
Continuous positive airway pressure: A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.</description>
          </group>
          <group group_id="O2">
            <title>Non African Americans</title>
            <description>82 Other race (non African Americans) Veterans.&#xD;
Continuous positive airway pressure: A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Sympathetic Activity (Catecholamines) and Oxidative Stress (8-isoprostane)</title>
          <description>Urine samples from participants over 24 hours will be analyzed for catecholamines and overnight sample will be partitioned for measurement of oxidative stress.&#xD;
The change in urine catecholamine values were calculated as 3 months - baseline.&#xD;
The mean and standard deviation in the sample are noted below.</description>
          <units>ng/mg creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Urine Epinephrine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="1.8"/>
                    <measurement group_id="O2" value="-0.26" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Norepinephrine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="12.2"/>
                    <measurement group_id="O2" value="-2.7" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3-5months.</time_frame>
      <desc>AE and SAE definitions used were consistent with clinicaltrials.gov.</desc>
      <group_list>
        <group group_id="E1">
          <title>African Americans</title>
          <description>138 Self identified African American&#xD;
Continuous positive airway pressure: A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.</description>
        </group>
        <group group_id="E2">
          <title>Non African Americans</title>
          <description>82 Other race (non African Americans) Veterans.&#xD;
Continuous positive airway pressure: A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitations of the study are as follows: Lower than anticipated enrollment of Whites &amp; lower than anticipated adherence to CPAP therapy overall, particularly in African American Veterans.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Bharati Prasad</name_or_title>
      <organization>Jesse Brown VAMC</organization>
      <phone>312-569-6343</phone>
      <email>bharati.prasad@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

